BioPorto reported higher third-quarter revenue from its NGAL products and the start of patient enrollment in a U.S. adult validation study, developments tied to its effort to expand use of the kidney-injury biomarker in the American market.
The Danish diagnostics company recorded DKK 8.8 million in NGAL revenue for the three months ended Sept. 30, up 22% from a year earlier at reported exchange rates. Growth was driven mainly by a 73% increase in U.S. NGAL sales for research use only, BioPorto said.
Five U.S. hospitals became customers for the research-use products during the quarter, bringing the reported total to 59 at quarter-end. BioPorto aims to reach more than 60 U.S. hospitals by the end of 2026.
The company reported total quarterly revenue of DKK 9.7 million, compared with DKK 10.4 million a year earlier. The prior-year total included DKK 2.9 million from an antibody business that BioPorto later sold. Excluding that business, revenue increased 28% to DKK 9.6 million from DKK 7.5 million.
BioPorto reported that its U.S. adult validation study moved into enrollment in the third quarter, after study sites were activated. The company did not provide an enrollment count or expected completion date.
Adjusted EBITDA loss was DKK 16.8 million, unchanged from the year-earlier quarter. Cash totaled DKK 53.2 million at Sept. 30, down from DKK 54.9 million at Dec. 31, 2025.
BioPorto maintained its 2026 forecasts for total revenue of DKK 38 million to DKK 48 million, NGAL revenue of DKK 33 million to DKK 42 million and an adjusted EBITDA loss of DKK 58 million to DKK 68 million. Management was scheduled to present the results in an investor webcast at 7 a.m. ET Nov. 19.



